Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector?

摘要

Background: During the last decade, the options to treat lung cancer patients with individualized, targeted therapy regimens have improved enormously. A subgroup of non-small cell lung cancer (NSCLC) patients with presence of anaplastic lymphoma kinase (ALK)-rearranged can respond to ALK inhibitors. Unfortunately, the tumor tissue based ALK analysis is not always possible and represents only a single-snapshot in time.